Success Metrics

Clinical Success Rate
65.4%

Based on 17 completed trials

Completion Rate
65%(17/26)
Active Trials
8(21%)
Results Posted
59%(10 trials)
Terminated
9(23%)

Phase Distribution

Ph phase_3
9
23%
Ph phase_4
3
8%
Ph phase_1
9
23%
Ph phase_2
6
15%

Phase Distribution

9

Early Stage

6

Mid Stage

12

Late Stage

Phase Distribution27 total trials
Phase 1Safety & dosage
9(33.3%)
Phase 2Efficacy & side effects
6(22.2%)
Phase 3Large-scale testing
9(33.3%)
Phase 4Post-market surveillance
3(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.7%

17 of 28 finished

Non-Completion Rate

39.3%

11 ended early

Currently Active

8

trials recruiting

Total Trials

39

all time

Status Distribution
Active(10)
Completed(17)
Terminated(11)
Other(1)

Detailed Status

Completed17
Terminated9
Recruiting6
Withdrawn2
Active, not recruiting2
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
39
Active
8
Success Rate
65.4%
Most Advanced
Phase 4

Trials by Phase

Phase 19 (33.3%)
Phase 26 (22.2%)
Phase 39 (33.3%)
Phase 43 (11.1%)

Trials by Status

terminated923%
withdrawn25%
enrolling_by_invitation13%
completed1744%
recruiting615%
unknown13%
active_not_recruiting25%
not_yet_recruiting13%

Recent Activity

Clinical Trials (39)

Showing 20 of 39 trialsScroll for more
NCT05076175Phase 2

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Recruiting
NCT06408259Phase 3

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Recruiting
NCT07271069

Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

Recruiting
NCT05369832Phase 4

An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

Terminated
NCT05319093

Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients

Terminated
NCT03440372Phase 3

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Terminated
NCT05688436

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

Recruiting
NCT03915769Phase 3

To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Completed
NCT03464097Phase 3

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Terminated
NCT06529406Phase 4

Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

Recruiting
NCT03467958Phase 3

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Terminated
NCT05335031

A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)

Completed
NCT05382715

A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative Colitis

Terminated
NCT06862960Phase 2

Ozanimod in Patients With Alzheimer's Disease

Not Yet Recruiting
NCT05809583

Define Predictors of Response to Ozanimod in UC Discovering Biomarkers in the Management of Ulcerative Colitis

Withdrawn
NCT05470985Phase 2

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy

Terminated
NCT05644665Phase 3

A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Terminated
NCT03440385Phase 3

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Completed
NCT06126835

A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants

Active Not Recruiting
NCT06073873

A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
39